Loading...
Mereo BioPharma Group plc
MREO•NASDAQ
Healthcare
Biotechnology
$1.63
$-1.31(-44.73%)
Mereo BioPharma Group plc (MREO) Financial Performance & Statements
Review Mereo BioPharma Group plc’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-100.00%
↓ 100.00%
Operating Income Growth
-66.68%
↓ 66.68%
Net Income Growth
-46.79%
↓ 46.79%
Operating Cash Flow Growth
-55.38%
↓ 55.38%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-69.34%
↓ 69.34%
ROIC
-80.01%
↓ 80.007%
Mereo BioPharma Group plc (MREO) Financial Statements
Explore quarterly and annual reports for Mereo BioPharma Group plc stock.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $257288.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$257288.00 |
| Gross Profit Ratio | $0.00 | |||
| R&D Expenses | $3.93M | $8.82M | $3.17M | $4.95M |
| SG&A Expenses | $7.27M | $6.45M | $6.20M | $7.87M |
| Operating Expenses | $11.20M | $15.28M | $9.37M | $12.81M |
| Total Costs & Expenses | $0.00 | $15.81M | $9.37M | $12.81M |
| Interest Income | $659000.00 | $881000.00 | $983000.00 | $559000.00 |
| Interest Expense | -$180000.00 | $375000.00 | $353000.00 | $331000.00 |
| Depreciation & Amortization | $0.00 | $274000.00 | $282000.00 | $257000.00 |
| EBITDA | -$11.20M | -$6.91M | -$14.37M | -$12.05M |
| EBITDA Ratio | ||||
| Operating Income | -$11.20M | -$15.28M | -$9.37M | -$12.81M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | -$1.69M | $8.23M | -$5.63M | $559000.00 |
| Income Before Tax | -$12.89M | -$7.05M | -$15.001M | -$12.26M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$12.89M | -$7.05M | -$15.001M | -$12.26M |
| Net Income Ratio | ||||
| EPS | -$0.10 | -$0.05 | -$500.10 | -$430.59 |
| Diluted EPS | -$0.10 | -$0.05 | -$500.10 | -$430.59 |
| Weighted Avg Shares Outstanding | $156.86M | $155.15M | $154.03M | $142.35M |
| Weighted Avg Shares Outstanding (Diluted) | $156.86M | $155.15M | $154.03M | $142.35M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan